TY - JOUR T1 - Estimating the Financial Impact of Gene Therapy* JF - medRxiv DO - 10.1101/2020.10.27.20220871 SP - 2020.10.27.20220871 AU - Chi Heem Wong AU - Dexin Li AU - Nina Wang AU - Jonathan Gruber AU - Rena Conti AU - Andrew W. Lo Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/31/2020.10.27.20220871.abstract N2 - We assess the potential financial impact of future gene therapies by identifying the 109 late-stage gene therapy clinical trials currently underway, estimating the prevalence and incidence of their corresponding diseases, developing novel mathematical models of the increase in quality-adjusted life years for each approved gene therapy, and simulating the launch prices and the expected spending of these therapies over a 15-year time horizon. The results of our simulation suggest that an expected total of 1.09 million patients will be treated by gene therapy from January 2020 to December 2034. The expected peak annual spending on these therapies is $25.3 billion, and the total spending from January 2020 to December 2034 is $306 billion. We decompose their annual estimated spending by treated age group as a proxy for U.S. insurance type, and consider the tradeoffs of various methods of payment for these therapies to ensure patient access to their expected benefits.Competing Interest StatementC.W., D.L., and N.W. report no conflicts. R.M.C. has no conflicts of interest to declare. Her research is funded by grants from the American Cancer Society, the National Cancer Institute, the Leukemia and Lymphoma Society and Arnold Ventures. None of these granting agencies funded her effort on this work. R.M.C. was also a special economic consultant to the US Food and Drug Administration's Office of Generic Drugs and is currently a voting committee member of ICER. None of these organizations had any role in the completion of this project, nor R.M.C.'s effort on this project. J.G. reports no conflicts. J.G. is a consultant for both the insurer Aetna, Inc and for the biotech company Sarepta, Inc. During the most recent 6 month period J.G. has received compensation from Aetna, MacMillan publishing, and Access Health, International. A.L. reports personal investments in private biotech companies, biotech venture capital funds, and mutual funds. A.L. is a co-founder and partner of QLS Advisors, a healthcare analytics and consulting company; an advisor to BrightEdge Ventures; a director of BridgeBio Pharma, Roivant Sciences, and Annual Reviews; chairman emeritus and senior advisor to AlphaSimplex Group; and a member of the Board of Overseers at Beth Israel Deaconess Medical Center and the NIH's National Center for Advancing Translational Sciences Advisory Council and Cures Acceleration Network Review Board. During the most recent six-year period, A.L. has received speaking/consulting fees, honoraria, or other forms of compensation from: AIG, AlphaSimplex Group, BIS, BridgeBio Pharma, Citigroup, Chicago Mercantile Exchange, Financial Times, FONDS Professionell, Harvard University, IMF, National Bank of Belgium, Q Group, Roivant Sciences, Scotia Bank, State Street Bank, University of Chicago, and Yale University.Funding StatementFunding support from the MIT Laboratory for Financial Engineering is gratefully acknowledged, but no direct funding was received for this study and no funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of this manuscript. The authors were personally salaried by their institutions during the period of writing (though no specific salary was set aside or given for the writing of this manuscript).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not Applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the manuscript are either commercial databases licensed by our respective universities or publicly available data. We intend to make our software available with an open-source license. https://projectalpha.mit.edu ER -